Shots:
- Mabwell’s Adalimumab Injection 9MW0113 (marketed as JUNMAIKANG in China), a Humira biosimilar, has received marketing authorization from Indonesia’s BPOM
- Adalimumab Injection 9MW0113, co-developed by Mabwell and Junshi Biosciences. Mabwell has submitted registration applications in multiple countries, including Jordan and Peru, and has agreements in over ten markets
- Adalimumab is a TNF blocker, binds TNF‑alpha and prevents it from interacting with p55 and p75 TNF receptors, used to treat various autoimmune conditions
Ref: Mabwell | Image: Mabwell | Press Release
Related News: Mabwell Doses First Patient in P-II Trial of 9MW3811 for Pathological Scarring
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
